



**Figure S6****A****B**

Figure S6. A. MRTX1719 in vitro activity (IC<sub>50</sub>) across a panel of *MTAP* WT and *MTAP* del cell line models (5-day viability assay, Crown Biosciences). B. MRTX1719 was tested in cell line- and patient derived-xenograft tumor models at 50 or 100 mg/kg administered by oral gavage QD. Average tumor volume is plotted +/- SEM (n=3/treatment group). Statistics were determined using a two-way ANOVA with significance indicated (\*, p < 0.05).